Sorcero Secures $42.5M Series B Financing Led by NewSpring Capital to Scale Its AI Platform, Accelerate Expansion Across Life Sciences

Sorcero获得由NewSpring Capital领投的4250万美元B轮融资，用于扩展其人工智能平台并加速在生命科学领域的扩张。

Agentic AI platform serves one-third of top 30 global pharma companies, delivering 18x faster insights and turning medical evidence into a driver for physician and patient adoption of novel therapies

代理型人工智能平台服务于全球前30大制药公司中的三分之一，提供快18倍的洞察，并将医学证据转化为推动医生和患者采用新型疗法的动力。

WASHINGTON, November 21, 2025-- Sorcero, the AI-powered intelligence platform for life sciences, today announced $42.5 million in Series B financing led by NewSpring Growth, NewSpring Capital's dedicated growth equity strategy that invests in fast-growing, industry-transforming technology companies.

华盛顿，2025年11月21日——生命科学领域的AI智能平台Sorcero今天宣布完成了4250万美元的B轮融资，此轮融资由NewSpring Capital专注成长型股权投资的策略基金NewSpring Growth领投，该基金投资于快速增长且改变行业的技术公司。

They are joined by Leawood Venture Capital and Blu Ventures, bringing the company's total capital raised to $59 million. The latest funding allows Sorcero to accelerate expansion across medical affairs, safety, scientific communications, and medical device segments globally, continue scaling its platform for a medical-insights driven engagement model, and meet life sciences' critical need to drive adoption of breakthrough therapies..

他们还获得了Leawood风险投资公司和Blu Ventures的加入，使得该公司的总融资额达到了5900万美元。最新的融资使Sorcero能够加速在全球医学事务、安全、科学传播和医疗器械领域的扩展，继续扩大其用于医学洞察驱动的参与模式的平台规模，并满足生命科学领域对推动突破性疗法采用的关键需求。

One-third of the top 30 global pharma companies use Sorcero to discover actionable insights from their medical data and drive effective evidence-based, personalized engagement with healthcare professionals (HCPs). Using Sorcero, companies are improving productivity in generating scientific evidence by up to 92%, accelerating insight generation by up to 72%, and delivering published evidence, manuscripts, and value dossiers two to five months faster than manual efforts..

全球前30大制药公司中有三分之一使用Sorcero从其医疗数据中发现可操作的洞察，并推动与医疗保健专业人员（HCP）的有效基于证据的个性化互动。通过使用Sorcero，公司生成科学证据的生产力提高了多达92%，洞察生成速度加快了多达72%，并且比手动工作快两到五个月交付已发表的证据、手稿和价值档案。

The Sorcero Intelligence Platform includes Sorcero Medical™, Sorcero SciComms™, Sorcero Safety™, Sorcero Medtech™, transforming how therapies get to market, accelerating content production, and improving patient outcomes. Sorcero uniquely combines Agentic AI specifically trained for life sciences, the industry's largest medically-enriched data pool, and a platform architecture designed for regulatory and privacy needs of life sciences..

Sorcero智能平台包括Sorcero Medical™、Sorcero SciComms™、Sorcero Safety™和Sorcero Medtech™，这些产品改变了疗法上市的方式，加速了内容生产，并改善了患者预后。Sorcero独创性地结合了专门为生命科学训练的代理型AI、行业中最大的医学强化数据池，以及专为生命科学领域的监管和隐私需求设计的平台架构。

'Our vision is to create a unified intelligence platform for the precision medicine era,' said Dipanwita Das, CEO and co-founder at Sorcero. 'We're pioneering a new evidence-based medical affairs model where science, personalized for physicians, drives engagement and product adoption. This puts doctors' evidence needs at the center and helps life sciences generate real-world insights radically faster, identify patients in need of specific treatments, and continually improve patient outcomes to drive healthcare provider adoption.'.

“我们的愿景是为精准医疗时代创建一个统一的智能平台，”Sorcero首席执行官兼联合创始人Dipanwita Das表示。“我们正在开创一种新的基于证据的医学事务模式，其中科学为医生个性化定制，推动参与和产品采用。这将医生的证据需求置于核心位置，帮助生命科学领域以更快的速度生成真实世界的见解，识别需要特定治疗的患者，并持续改善患者结果，从而推动医疗机构的采纳。”

Optimizing life sciences for a disruptive era

优化生命科学以应对颠覆性时代

Precision medicine and specialty drugs now represent over 80% of new approved products. Companies spend billions on research and development, but new complex medicines take years to secure broad adoption and coverage, with effective therapies often failing to reach eligible patients. With over 1,300 drugs in Phase III development and with 76% of new products securing less than 50% payor coverage in six months, quality and speed-to-market of scientific publishing and evidence are critical and medical affairs teams require new approaches to deliver the precision targeting and evidence today's therapies require..

精准医疗和特效药物如今占新批准产品的80%以上。公司花费数十亿美元在研发上，但新型复杂药物需要数年时间才能获得广泛采用和覆盖，有效的疗法常常无法惠及符合条件的患者。目前有1300多种药物处于第三阶段开发，其中76%的新产品在六个月内获得不到50%的支付方覆盖。科学出版和证据的质量与上市速度至关重要，医学事务团队需要新的方法来提供当今疗法所需的精准定位和证据。

An estimated 70% of healthcare professionals (HCP) believe that pharma representatives don't understand their needs and 62% are overwhelmed by the volume of irrelevant promotional content. Inadequate understanding of patient and customer needs is one of the leading causes why drug launches underperform..

据估计，70%的医疗保健专业人士（HCP）认为制药代表不了解他们的需求，62%的人被大量无关的促销内容淹没。对患者和客户需求理解不足是药品上市表现不佳的主要原因之一。

Sorcero unifies fragmented global data and real-world evidence into actionable, compliant intelligence. The platform integrates hundreds of sources to create a 360-degree view of over 40 million HCPs and 100 million published scientists worldwide. Medically-tuned AI agents ingest, analyze, and validate information to ensure 96.1% clinical inclusion accuracy, surpassing the 95% FDA regulatory threshold and PhD-level human performance..

Sorcero 将分散的全球数据和真实世界证据整合为可操作且合规的情报。该平台集成了数百个来源，创建了超过 4000 万名医疗保健专业人员（HCP）和 1 亿名全球发表论文的科学家的 360 度视图。经过医学调优的 AI 智能体对信息进行摄取、分析和验证，确保临床收录准确率达到 96.1%，超过了 95% 的 FDA 监管阈值以及博士级人类表现。

Unlike traditional medical outreach informed primarily by U.S.-only claims data and prescription volumes, Sorcero reads more than 263 million publications and 1.3 billion citations globally, including every congress session, report, survey, CRM interaction, safety case, and medical inquiry. This identifies which KOLs and doctors are active in specific research areas or treating relevant patient populations.

与主要依赖美国本土索赔数据和处方量的传统医疗推广不同，Sorcero阅读了超过2.63亿份出版物和13亿条全球引文，包括每次大会会议、报告、调查、CRM互动、安全案例和医疗咨询。这确定了哪些关键意见领袖（KOL）和医生在特定研究领域活跃或治疗相关患者群体。

The platform continuously monitors product efficacy and safety, providing the precise, real-time insights precision medicine practitioners now expect, and allowing life sciences customers to engage HCPs with the right information at the right time..

该平台持续监控产品的功效和安全性，提供精准医学从业者现在所期望的精确、实时的洞察，并使生命科学领域的客户能够在正确的时间向医疗保健专业人员提供正确的信息。

Investor and market validation

投资者和市场验证

'We see tremendous potential in AI helping pharma engage the right doctors with the right evidence at the right time and ultimately serve patients who can't wait months for critical information on life-changing therapies,' said Hart Callahan, NewSpring General Partner. 'Sorcero is uniquely positioned to become the vertical AI platform precision medicine demands and provide the medical insights that get treatments to patients faster.'.

“我们看到人工智能在帮助制药公司以正确的证据在正确的时间吸引正确的医生方面具有巨大的潜力，并最终服务于那些不能等待数月获取改变生命疗法关键信息的患者，”NewSpring普通合伙人哈特·卡拉汉表示。“Sorcero独具优势，有望成为精准医疗所需的垂直人工智能平台，并提供有助于更快将治疗方案带给患者的医学见解。”

'We invested in Sorcero because their time-to-replicate advantage and expanding data network create a widening moat as they scale,' said Dan Goldsmith, life sciences software veteran and investor. 'As specialty therapeutics become the norm, life sciences organizations must be data-driven and science-focused to improve therapy adoption.

“我们投资Sorcero是因为它们的复制时间优势和不断扩展的数据网络在规模化过程中创造了越来越宽的护城河，”生命科学软件资深人士兼投资人丹·戈德史密斯表示。“随着专科疗法成为常态，生命科学组织必须以数据为驱动并聚焦科学，以提高疗法的采用率。”

There's a lot of hype around AI, but few companies deliver measurable value at scale. Sorcero stands out as a proven AI platform—driving real outcomes, accelerating evidence generation, and transforming how therapies reach patients.'.

围绕人工智能有很多炒作，但很少有公司能够大规模提供可衡量的价值。Sorcero 作为一个经过验证的人工智能平台脱颖而出——推动实际成果，加速证据生成，并改变疗法惠及患者的方式。

Sorcero is backed by exclusive data and deep AI and data partnerships with Google Cloud, Springer Nature, ServiceNow, USDM Life Sciences, and Snowflake, with built-in GxP, GVP, GDPR, and SOC II compliance and pharmacovigilance to meet the needs of a highly regulated industry. The company's recent acquisition of Axiom Health accelerates its expansion into the medical device market..

Sorcero 得到了来自谷歌云、施普林格自然、ServiceNow、USDM生命科学和Snowflake的独家数据及深度AI和数据合作的支持，内置GxP、GVP、GDPR和SOC II合规性以及药物警戒，以满足高度监管行业的需求。该公司最近对Axiom Health的收购加速了其向医疗器械市场的扩张。

The Sorcero platform is available directly and via the NIH STRIDES and Google Cloud Marketplace today, as well as a growing number of digital marketplaces. To learn how Sorcero is pioneering a new insight-driven medical & market access model in life sciences, visit www.sorcero.com.

Sorcero平台现已通过NIH STRIDES和Google Cloud Marketplace以及越来越多的数字市场直接提供。要了解Sorcero如何在生命科学领域开创一种新的洞察驱动型医学和市场准入模式，请访问www.sorcero.com。

About Sorcero

关于Sorcero

Sorcero's medically-tuned intelligence platform transforms life sciences decision-making, accelerating patient access to life-saving treatments. By delivering global insights, we empower industry leaders to deliver breakthrough therapies. Founded in 2018 by pioneers in AI, public health, and personalized content, Sorcero is a Certified B Corp headquartered in Washington, DC.

Sorcero的医学智能平台改变了生命科学决策，加速患者获得挽救生命的治疗。通过提供全球视野，我们助力行业领袖推出突破性疗法。Sorcero成立于2018年，由人工智能、公共卫生和个性化内容领域的先驱者创立，是一家总部位于华盛顿特区的认证共益企业（Certified B Corp）。

The company's innovations have been recognized by over a dozen awards, including as Google's Partner of the Year for Healthcare & Life Sciences, America's Most Innovative Companies by Fortune, Inc. 5000 fastest-growing private companies, and seven foundational medical AI patents. Learn more at: www.sorcero.com..

该公司创新成果荣获十余项大奖，包括谷歌年度医疗与生命科学合作伙伴、《财富》杂志评选的美国最具创新力公司、Inc. 5000增长最快的私营企业，以及七项基础医疗人工智能专利。欲了解更多信息，请访问：www.sorcero.com。

About NewSpring

关于新泉

For more than 25 years, NewSpring Capital has worked alongside founders and management teams in the lower-middle market, providing capital, operational support, and strategic guidance to help businesses scale. With over $3.5 billion in assets under management and more than 250 investments completed, we bring operational experience and investment expertise to build market-leading companies across sectors such as technology, healthcare, business services, consumer, and industrials.

二十多年来，NewSpring Capital 一直与中低端市场的创始人和管理团队合作，提供资本、运营支持和战略指导，帮助企业实现规模扩张。凭借超过 35 亿美元的资产管理规模和完成的 250 多项投资，我们在技术、医疗保健、商业服务、消费和工业等多个领域，运用运营经验和投资专长打造市场领先的企业。

Through five distinct strategies covering the spectrum from growth equity and control buyouts to mezzanine debt, we tailor our approach to each company's stage and goals, always with a focus on sustainable growth. As specialists in the lower-middle market, we support growth that leads to more predictable outcomes.

通过涵盖从成长型股权、控股收购到夹层债务的五种不同策略，我们根据每家公司的阶段和目标量身定制方法，始终专注于可持续增长。作为低端中型市场的专家，我们支持导向更可预测结果的增长。

At NewSpring, we are as invested in your outcome as you are..

在 NewSpring，我们对您的成果和您一样投入。